- Advertise
- Contact Us
- Contribute
- Editorial Info
- Terms and Conditions
- Privacy Policy
- Do Not Sell My Personal Information
- About Us
© 2021 MJH Life Sciences™ and Endocrinology Network. All rights reserved.
American Diabetes Association
Coverage of the American Diabetes Association's 81st Scientific Sessions (ADA 2021).
ADA 2021 Expert Perspective: Dr. Diana Isaacs's Top 5 CGM Studies
July 07, 2021
Diana Isaacs, PharmD, offers perspective on her top 5 CGM-related studies or presentations from the American Diabetes Association's 81st Scientific Sessions.
DISCOVER Details Gradual Uptake, Need for Improvement in Prescribing of SGLT2 Inhibitors, GLP-1 RAs
July 02, 2021
Insights from the DISCOVER registry were presented at the American Diabetes Association's 81st Scientific Sessions. Check out our Q&A with study presenter Suzanne Arnold, MD, of St. Luke's Mid America Heart Institute.
ADA 2021: Top Data and Other Highlights from the American Diabetes Association's 81st Scientific Sessions
June 30, 2021
Our editorial staff has selected a shortlist of highlighted data and summary slides on their picks of the most important data to be released at the American Diabetes Association's 81st Annual Scientific Sessions.
ADA 2021: Tirzepatide Demonstrates Potential in Type 2 Diabetes with SURPASS Trials
June 29, 2021
Data from the SURPASS program presented at ADA 2021 provide insight into the effects of tirzepatide on HbA1c control and body weight in a variety of different patient populations as both an add-on and monotherapy.
ADA 2021: Sotagliflozin Impact in Patients with Type 2 Diabetes Highlighted in Special Session
June 29, 2021
While still waiting for regulatory approval, the SCORED and SOLOIST trial have demonstrated the impact of sotagliflozin, a dual SGLT1/2 inhibitor, on patients with type 2 diabetes and chronic kidney disease or heart failure.
AI-Enabled KidneyIntelX Monitors SGLT2 Inhibitor Response, Disease Progression in Diabetic Kidney Disease
June 29, 2021
Using banked samples from the CANVAS trial, investigators demonstrate the ability of KidneyIntelX to monitor therapeutic response to SGLT2 inhibitors and predict disease progression in patients with type 2 diabetes and chronic kidney disease.
AMPLITUDE-O: Efpeglenatide Shows Promise for Reducing CV, Kidney Events in Patients with Diabetes
June 28, 2021
Data from the AMPLITUDE-O trial demonstrates the effects of the exendin-4-based GLP-1 RA efpeglenatide on cardiovascular and renal outcomes among patients with type 2 diabetes and cardiovascular disease or kidney disease.
REDUCE-IT BMI: Icosapent Ethyl Provides Consistent Benefit, Regardless of BMI
June 28, 2021
Deepak Bhatt, MD, MPH, discusses the results of REDUCE-IT BMI, which examined effects of icosapent ethyl vs placebo based on baseline BMI, that he presented at ADA 2021.
100 Years of Insulin: Perspective from a Provider with Type 1 Diabetes
June 28, 2021
Using the ADA's celebration of the 100-year anniversary of the discovery of insulin as a backdrop, resident Advisory Board member Adam Sturts, DO, reflects on the history, present, and future of insulin from the perspective of a provider and a patient with type 1 diabetes.
Semaglutide 2.0 mg Proves Superiority vs Ozempic for Glycemic Control, Weight Loss in SUSTAIN FORTE
June 28, 2021
A pair of studies presented at ADA 2021 detail the effects of an investigational 2.0 mg dose of semaglutide compared to semaglutide 1.0 mg (Ozempic) on glycemic control and body weight in patients with type 2 diabetes in SUSTAIN FORTE.